POS0510 EPIDEMIOLOGY OF COCAINE AND HALLUCINOGEN USE DISORDER HOSPITALIZATIONS IN RHEUMATIC DISEASES

Background: Cocaine use disorder is a frequent cause of drug disorders in the U.S. Although hallucinogen less common, both are potentially preventable public health issues. To our knowledge, epidemiological studies estimating burden cocaine or common Musculoskeletal diseases (MSDs) lacking. Objectives: assess national time-trends and people with MSDs Methods: This study used National Inpatient Sample (NIS), de-identified all-payer inpatient care database ( https://www.hcup-us.ahrq.gov/nisoverview.jsp ) from 1998-2014. The NIS 20% stratified sample hospital discharges It commonly to derive estimates hospitalization outcomes. was defined validated approach as presence following International Classification Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes: disorder, 304.2x, 305.6x; 304.5x 305.3x; hospitalizations for remission, counseling, rehabilitation detoxification were excluded, previous studies. identified based on respective ICD-9 codes, (5-9), non-primary position: Gout: 274.xx; rheumatoid arthritis (RA): 714.xx; Fibromyalgia: 729.1; osteoarthritis (OA): 715.xx; low back pain (LBP): 724. Results: In 1998-2000, highest frequency LBP: LBP (n=5,914), followed by OA (n=4,931), gout (n=2,093), RA (n=2,026), fibromyalgia (n=1,620). 2013-2014, order changed slightly (n=22,185), (n=16,810), (n=10,570), (n=8,975), (n=5,680). Respective rates per 1 million 2013-2014 relative increase 1998-2000 were: Gout, 10.2 (increase, 4.1-fold); OA, 21.4 (3.5-fold); fibromyalgia, 5.48 (2.5-fold); RA, 8.66 (3.4-fold); LBP, 16.22 (1.8-fold; figure 1). Figure 1. Time-trends (A), non-home discharge (B), in-hospital mortality (C) 100,000 claims. x-axis shows rate claims y-axis periods follows: (n=176), (n=63), (n=42), (n=41) (n<10; cells 10 fewer reported <10 guidance). similar, numbers (n=525) (n=400), (n=395), (n=135) (n=125). US 0.13 25-fold); 0.39 (5.5-fold); 0.12 (2-fold); 0.38 (8.5-fold); 0.51 (2-fold; Conclusion: confirmed an increasing both, 5 over 17-year period 1998-2014 Acknowledgements: John D. Cleveland, MS University Alabama at Birmingham performing data analyses according protocol. Disclosure Interests: Jasvinder Singh Speakers bureau: JAS speaker’s bureau Simply Speaking. member executive Outcomes Measures Rheumatology (OMERACT), organization that develops outcome measures rheumatology receives arms-length funding 12 companies., Consultant of: consultant fees Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio Health, Medscape, WebMD, Two labs Inc., Adept Field Solutions, Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Practice Point communications, Institutes Health American College Rheumatology.